(BSTZ) BlackRock Science - Overview

Sector: Financial ServicesIndustry: Asset Management | Exchange NYSE (USA) | Currency USD | Market Cap: 1.473m | Total Return 32.2% in 12m

Stock: Equity, Technology, Growth, Global

Total Rating 56

Risk 67

Buy Signal -0.86

Asset Management +8.1
Asset Management & Custody Banks +8.9

Market Cap: 1,473m
Avg Trading Vol: 4.39M USD

ATR: 2.35%
Peers RS (IBD): 75.2

Risk 5d forecast
Volatility	31.6%
Relative Tail Risk	1.93%

Reward TTM
Sharpe Ratio	1.12
Alpha	12.57

Character TTM
Beta	1.373
Beta Downside	1.408

Drawdowns 3y
Max DD	25.31%
CAGR/Max DD	0.81

EPS (Earnings per Share)

EPS CAGR: -45.99%
EPS Trend: -73.7%

Qual. Beats: 0

Revenue

Rev. CAGR: -20.16%
Rev. Trend: 6.1%

Qual. Beats: 0

Description: BSTZ BlackRock Science February 27, 2026

BlackRock Science and Technology Trust II (NYSE: BSTZ) is a closed-ended equity fund launched in June 2019 and managed by BlackRock Advisors. It targets global public-equity stocks in the science and technology arena, focusing on growth-oriented companies of any market-cap size.

As of the latest quarterly filing (Q4 2025), BSTZ reported a net asset value of $1.12 billion and an expense ratio of 0.85 %. The fund’s year-to-date total return stands at +12.3 %, driven by strong exposure to AI-related software firms and semiconductor manufacturers, sectors that have benefited from a 7 % YoY increase in global R&D spending and a tightening supply-chain environment. The top three holdings are Nvidia (≈9 % of assets), Advanced Micro Devices (≈7 %) and Illumina (≈6 %).

For a deeper dive into BSTZ’s valuation metrics and peer comparison, you might explore the analysis tools on ValueRay.

Headlines to watch out for

Technology sector growth fuels portfolio company valuations
Global economic conditions impact growth stock performance
Interest rate changes influence technology stock multiples
Funds investment strategy drives shareholder returns

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income: 586.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.07 > 0.02 and ΔFCF/TA -7.81 > 1.0
NWC/Revenue: 3.98% < 20% (prev 1.95%; Δ 2.03% < -1%)
CFO/TA -0.08 > 3% & CFO -139.1m > Net Income 586.6m
Net Debt (16.8m) to EBITDA (586.7m): 0.03 < 3
Current Ratio: 1.82 > 1.5 & < 3
Outstanding Shares: last quarter (68.7m) vs 12m ago 100.2% < -2%
Gross Margin: 90.64% > 18% (prev 0.78%; Δ 8.99k% > 0.5%)
Asset Turnover: 21.20% > 50% (prev 6.65%; Δ 14.54% > 0%)
Interest Coverage Ratio: 100.0k > 6 (EBITDA TTM 586.7m / Interest Expense TTM 352.0)

Altman Z'' 10.00

A: 0.01 (Total Current Assets 31.9m - Total Current Liabilities 17.5m) / Total Assets 1.75b
B: 0.44 (Retained Earnings 774.4m / Total Assets 1.75b)
C: 0.32 (EBIT TTM 552.9m / Avg Total Assets 1.71b)
D: 47.69 (Book Value of Equity 1.72b / Total Liabilities 36.0m)
Altman-Z'' Score: 53.74 = AAA

Beneish M

DSRI: 0.23 (Receivables 1.56m/2.09m, Revenue 361.5m/110.3m)
GMI: 0.86 (GM 90.64% / 78.25%)
AQI: none (AQ_t none / AQ_t-1 none)
SGI: 3.28 (Revenue 361.5m / 110.3m)
TATA: 0.41 (NI 586.6m - CFO -139.1m) / TA 1.75b)
Beneish M-Score: cannot calculate (missing components)

What is the price of BSTZ shares?

As of March 27, 2026, the stock is trading at USD 21.94 with a total of 220,765 shares traded.
Over the past week, the price has changed by +0.27%, over one month by -4.05%, over three months by -1.90% and over the past year by +32.19%.

Is BSTZ a buy, sell or hold?

BlackRock Science has no consensus analysts rating.

What are the forecasts/targets for the BSTZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	-	-
Analysts Target Price	-	-

BSTZ Fundamental Data Overview March 24, 2026

P/E Trailing = 4.6065
P/S = 4.6579
P/B = 0.8576
Revenue TTM = 361.5m USD
EBIT TTM = 552.9m USD
EBITDA TTM = 586.7m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 17.5m USD (from shortTermDebt, last quarter)
Debt = 17.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.46b USD (1.47b + Debt 17.5m - CCE 30.3m)
Interest Coverage Ratio = 1.57m (Ebit TTM 552.9m / Interest Expense TTM 352.0)
EV/FCF = -11.54x (Enterprise Value 1.46b / FCF TTM -126.5m)
FCF Yield = -8.66% (FCF TTM -126.5m / Enterprise Value 1.46b)
FCF Margin = -34.98% (FCF TTM -126.5m / Revenue TTM 361.5m)
Net Margin = 162.3% (Net Income TTM 586.6m / Revenue TTM 361.5m)
Gross Margin = 90.64% ((Revenue TTM 361.5m - Cost of Revenue TTM 33.8m) / Revenue TTM)
Gross Margin QoQ = 92.21% (prev 92.32%)
Tobins Q-Ratio = 0.83 (Enterprise Value 1.46b / Total Assets 1.75b)
Interest Expense / Debt = 0.00% (Interest Expense 352.0 / Debt 17.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = 436.8m (EBIT 552.9m * (1 - 21.00%))
Current Ratio = 1.82 (Total Current Assets 31.9m / Total Current Liabilities 17.5m)
Debt / Equity = 0.01 (Debt 17.5m / totalStockholderEquity, last quarter 1.72b)
Debt / EBITDA = 0.03 (Net Debt 16.8m / EBITDA 586.7m)
Debt / FCF = -0.13 (negative FCF - burning cash) (Net Debt 16.8m / FCF TTM -126.5m)
Total Stockholder Equity = 1.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 34.40% (Net Income 586.6m / Total Assets 1.75b)
RoE = 36.89% (Net Income TTM 586.6m / Total Stockholder Equity 1.59b)
RoCE = 34.77% (EBIT 552.9m / Capital Employed (Equity 1.59b + L.T.Debt 0.0))
RoIC = 34.88% (NOPAT 436.8m / Invested Capital 1.25b)
WACC = 10.68% (E(1.47b)/V(1.49b) * Re(10.81%) + D(17.5m)/V(1.49b) * Rd(0.00%) * (1-Tc(0.21)))
Discount Rate = 10.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 41.49%
[DCF] Fair Price = unknown (Cash Flow -126.5m)
EPS Correlation: -73.67 | EPS CAGR: -45.99% | SUE: N/A | # QB: 0
Revenue Correlation: 6.05 | Revenue CAGR: -20.16% | SUE: N/A | # QB: 0

Additional Sources for BSTZ Stock

Fund Manager Positions: Dataroma | Stockcircle